New Antibiotics Show Limited Impact on Drug-Resistant Infection Deaths

A significant US study, published in the European Medical Journal (EMJ) on April 12, 2026, indicates that new antibiotics have largely failed to reduce overall mortality rates from difficult-to-treat resistant (DTR) infections, despite their increased availability. The study, which analyzed over 8 million hospital encounters between 2016 and 2023, identified more than 5,000 patients with confirmed DTR Gram-negative infections caused by pathogens such as Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii. While newer antibiotics active against these pathogens saw an increase in initial prescribing from 4% in 2016 to 15% in 2023, the vast majority of patients (84% even in 2023) still received initial antibiotic therapy that was not effective against the infecting organism based on laboratory susceptibility testing. This critical mismatch, termed in-vitro discordant therapy, leads to delays in administering effective treatment, a factor known to significantly worsen outcomes in severe infections. After adjusting for various patient, hospital, and pandemic-related factors, researchers found no meaningful change in mortality over time for most infections caused by these resistant bacteria. An exception was noted in bloodstream infections caused by *Pseudomonas aeruginosa*, where a modest decline in mortality was observed. These findings underscore that merely having access to advanced antibiotics is insufficient if they are not utilized promptly and appropriately, highlighting a critical gap in clinical practice. The global context of antimicrobial resistance (AMR) further amplifies the concerns raised by this study. AMR is recognized as a major global health threat, responsible for millions of deaths worldwide. A landmark study published in The Lancet in September 2024, involving the Global Research on Antimicrobial Resistance (GRAM) Project, estimated that over 39 million people could die from antibiotic-resistant infections between 2025 and 2050. The study revealed that more than one million people died directly from AMR globally each year between 1990 and 2021, with projections indicating a nearly 70% increase in annual deaths by 2050 compared to 2022. For India, the implications are particularly severe. The country has been referred to as the 'AMR capital of the world' and faces a significant burden of infectious diseases, coupled with high and often unregulated antibiotic consumption. Over 300,000 lives have been lost each year in India due to AMR since 1990. In 2021 alone, an estimated 267,000 deaths were directly attributable to AMR, and nearly a million deaths were associated with it. Key factors contributing to AMR in India include an overburdened public health system, limited laboratory capacity for accurate diagnosis, inexpensive and widely available antibiotics without prescriptions, and inconsistent infection prevention and control practices. Without concerted action, AMR-associated deaths in India could escalate to 1.2 million by 2030. Recent analyses further highlight the escalating crisis. A February 2026 study published in Antimicrobial Resistance & Infection Control reported that deaths from antibiotic-resistant lower respiratory infections in 2021 were almost three times higher than those from susceptible infections, particularly impacting low-income countries and adults over 50. The World Economic Forum, in October 2024, also cited The Lancet study, projecting a 70% increase in deaths from drug-resistant infections by 2050, reaching a staggering 169 million. This report emphasized that the most difficult-to-treat infections are now outpacing antibiotic development, and in many parts of the world, a lack of access to effective first-line antibiotics is a significant problem, contributing to the rise and spread of resistance. The European Medical Journal, established in 2012, is an independent, peer-reviewed, open-access journal dedicated to disseminating scientific insights across various medical fields. Its mission includes elevating the quality of healthcare globally and providing open-access education to healthcare professionals. The publication of this study in EMJ reinforces the urgency of the AMR crisis and the need for a multi-faceted approach, including improved infection prevention and control, better diagnostic tools to ensure appropriate and timely treatment, and continued research into novel antimicrobials, alongside robust antibiotic stewardship programs.

Frequently Asked Questions

Read Full Story on Quick Digest